IDEA Bio-Medical
Image-based Screening Platforms
Company Overview
Snapshot
Founded in January 2007 by Shlomo Turgeman, IDEA Bio-Medical operates with 1–10 employees. The company specializes in image-based screening platforms and has established a strategic partnership with European research teams to develop solutions in super-resolution microscopy, regenerative medicine, immunology, and biomedicine.
Business overview
IDEA Bio-Medical is a commercial-stage company that develops solutions for biological cell-imaging research, drug-discovery automation, and diagnostics. Its core technology includes platforms like WiScan Hermes, a high-definition, ultra-fast biological cell-imaging system. The company's systems are designed to enhance the output of drug-discovery processes and reduce R&D costs in biomedical and pharmaceutical sectors, serving markets in the United States, Europe, and Israel.
Strategic signal
In March 2017, IDEA Bio-Medical introduced a new feature for spatio-temporal analysis of rare events using high-content microscopy. This development signals the company's ongoing commitment to advancing its imaging technology, providing researchers with more sophisticated tools for detailed cellular analysis, and enhancing its competitive position in the drug discovery and biomedical research markets.
Company Intelligence Q&A
- When was IDEA Bio-Medical founded?
- IDEA Bio-Medical was founded in January 2007.
- Who founded IDEA Bio-Medical?
- IDEA Bio-Medical was founded by Shlomo Turgeman.
- What is IDEA Bio-Medical's primary product?
- IDEA Bio-Medical's primary product is the WiScan Hermes, a high-definition, ultra-fast biological cell-imaging system.
- What was a key product development for IDEA Bio-Medical in 2017?
- In March 2017, IDEA Bio-Medical offered a new feature for spatio-temporal analysis of rare events measures using high-content microscopy.
- What strategic partnership did IDEA Bio-Medical form?
- IDEA Bio-Medical joined forces with European research teams to develop solutions in super-resolution microscopy, regenerative medicine, immunology, and biomedicine, as part of the European Union's seventh program.